Efficacy of Eye Movement Desensitization & Reprocessing Versus Cognitive Behavioral Therapy in Post-Traumatic Stress and Depressive Disorders
1 other identifier
interventional
100
1 country
1
Brief Summary
Post-Traumatic Stress Disorder(PTSD) develops after exposure to or witnessing traumatic events. PTSD is highly comorbid and individuals with PTSD usually report Major Depressive Disorder(MDD). Common treatment choices for PTSD and MDD are either EMDR or CBT, however, little is known about their comparative efficacy, especially in Pakistan. Therefore, this Randomized Controlled Trial(RCT) aims at determining the comparative efficacy of EMDR vs CBT in Pakistan. This study will also examine the association between reduction in symptoms of PTSD and MDD over course of treatment. In this regard, two arms Crossover Randomized Controlled Trial(RCT) with Repeated Measures Design will be selected. This study will be conducted at two rehabilitation centres and patients will be screened at Time:01, baseline; Time:02, during treatment; Time:03, post treatment and Time:04, 06 months follow-up. All analyses will be performed according to intention-to-treat principle. Variations in symptoms will be analysed by using descriptive statistics, χ2 tests, t-tests, and one way ANOVA. To examine changes in PTSD and MDD across time and to check efficacy of each treatment, a series of Linear Mixed Models will be run. Furthermore, a series of multi-level lagged mediation analysis will be performed to check bi-directional mediation between changes PTSD and MDD over time. This protocol has outlined the rationale for determining efficacy of EMDR and CBT in Pakistan. It will help in answering a broad range of questions concerning efficacy of newly developed evidence-based treatments. Moreover, it may also guide future research on the treatment of PTSD and MDD in the developing countries.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 11, 2019
CompletedFirst Posted
Study publicly available on registry
July 16, 2019
CompletedStudy Start
First participant enrolled
October 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2021
CompletedFebruary 2, 2023
February 1, 2023
10 months
July 11, 2019
February 1, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Measurement of Change in the symptoms of Post Traumatic Stress Disorder
Clinician-Administered Post Traumatic Stress Disorder Scale-5 (Weathers, Blake, et al., 2013) These diagnostic tools will be used to assess the symptoms of Post Traumatic Stress Disorder. Any changes in the level of PTSD will be noted with respect to Pre, Mid and Post treatment stages The total symptom severity score is calculated by summing severity scores for the 20 * Criterion A (items 1-5); (Exposure to actual or threatened death) * Criterion B (items 6-7); (Presence of intrusion symptoms associated with the traumatic events) * Criterion C (items 8-14); (Persistent avoidance of stimuli associated with the traumatic events) * Criterion D (items 15-20). (Negative alterations in cognitions and mood associated with the traumatic events) Severity Rating 0. Absent: 1. Mild / subthreshold:. 2. Moderate / threshold: 3. Severe / markedly elevated: 4. Extreme / incapacitating:
1st week (Baseline/pre-treatment screening, T-1); six weeks (during treatment screening, T-2); 12 weeks (post-treatment assessment, T-3). Finally, three months (follow up assessment, T-4).
Measurement of Socio Demographic Profile
Socio-demographic characteristics of the patients, like age, gender, marital status, occupation and social background
1st week at start of treatment, i.e, from date of randomization
Secondary Outcomes (1)
Measurement of Change in the symptoms of major depression
1st week (Baseline/pre-treatment screening, T-1); six weeks (during treatment screening, T-2); 12 weeks (post-treatment assessment, T-3). Finally, three months (follow up assessment, T-4).
Study Arms (2)
EMDR Therapy
OTHEROne arm will be a group subjected to EMDR Therapy
CBT Therapy
OTHERother arm will be a group subjected to CBT Therapy
Interventions
Eligibility Criteria
You may not qualify if:
- The following patients will be excluded:
- Patients below the age of 18 years and above 60 years as this study is not on children or older patients;
- Patients who can't move their hands and eyes/or can't perform basic movements;
- Patients who are unconscious for longer periods and unable to recover consciousness;
- Patients not meeting the basic screening criteria of PTSD/ PTSD is not the main problem;
- Patients with severe intellectual impairments, since such patients are difficult to communicate.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Anwar Khan
Karak, KPK, 27200, Pakistan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
July 11, 2019
First Posted
July 16, 2019
Study Start
October 1, 2020
Primary Completion
August 1, 2021
Study Completion
October 1, 2021
Last Updated
February 2, 2023
Record last verified: 2023-02
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, CSR
- Time Frame
- it will available next year on line
- Access Criteria
- will be on-line accessible
the data obtained will be published in peer reviewed journals